New startup ideas · Health and bio · Healthcare and bio
startup idea
Datavena
The marketplace where your biology earns royalties from drug developers.
Datavena is a consumer app where people connect wearables, genomes and health records and license access to pharma and AI labs - and get paid recurring royalties every time their data trains a model.
- Marketplace
- Consumer
- $100B+ market
- Creates a new category
- Global from day one
3/5
venture judge
13
similar startups, last 2 years (121 all-time)
97%
of 4 nearest real companies still alive
yes
8 matching federal grants and programs
Direction supported by government programs and grants
Scorecard
One score that balances how trendy the idea is, the demand for it and its potential for 100x, with competition measured relative to every other idea in the catalog. Recent startup trends first, government priorities second.
64
Idea Score, 0-100 · raw 39.0 x 1.64
Crowded
competition: more crowded than 79% of ideas · headwind x0.60
+4.7
government priorities, secondary (151 matching grants)
Trend
69
Is the wave forming now? 2025-26 entrants vs 2023-24, rounds since 2025, the sector's live-batch direction, the 2026 trend analyst.
- Entrants 2025-26 vs 2023-24 (similar companies)85
- Rounds announced 2025+ in the sector68
- Sector direction (live batch)100
- 2026 trend analyst25
Demand
43
Does anyone want it? YC's current RFS, companies already paid for something similar, the operator judge, founders' yes-rate in decks, readers who would run the test.
- YC asks for it (current RFS: idea / sector)30
- Someone already pays (similar companies, recent / all-time)100
- Operator judge: real pain0
100x potential
60
Can it return a fund? The venture judge (double weight), market-size and moat axes, neighbours still alive, the technologist judge.
- Venture judge50
- Market size axis100
- Moat axis80
- Neighbours still alive31
- Technologist judge50
Score = 100 x cbrt(Trend x Demand x 100x) x (1 - 0.5 x crowding) + government bonus (max 5), calibrated so the 95th-percentile idea scores 90 (order never changes). A geometric mean: a weak pillar cannot be papered over. Percentiles are among the 272 ideas in the catalog; the terms matched were marketplace, biology, earns, royalties, drug, developers, consumer, connect.
The idea in full
- What
- Datavena is a consumer app where people connect wearables, genomes and health records and license access to pharma and AI labs - and get paid recurring royalties every time their data trains a model. The deep tech is a federated compute layer built over roughly three years of R&D: buyers' models train against member data inside secure enclaves, so raw data never leaves the member's custody and every training run is metered and billed. Consumers join self-serve; the supply side is the product, and the capital goes into ops - onboarding, verification, and device partnerships that preinstall Datavena at the point of sale.
- Why now
- The brief counts five recent companies pitching drug discovery and Atlas Discovery (YC S26) is funded to predict human response to drugs in clinical trials - the demand side for real human phenotype data is crowded and paying, while elegslab's NAMs platform shows regulators pushing toward alternatives to animal data; nobody in the brief is building the consented human supply side.
- Wedge: first customer and entry point
- Recruit 50,000 wearable owners in one disease community (type 2 diabetes) with a guaranteed first-year royalty, and sign two AI-biotech buyers for that single high-value cohort before generalizing.
- Path to 100x
- Global drug R&D spend exceeds $250B a year and is shifting toward models trained on human rather than animal data; a royalty marketplace creates a category - individuals as recurring data licensors - and the winner is whoever owns the consumer installed base, since buyers go where the members are. 100x is tens of millions of members, device-maker preinstall deals as the distribution lock, and a take rate on a multi-billion-dollar annual flow of training-access fees.
- Ceiling
- If synthetic and organoid-derived data (the NAMs wave) gets good enough, demand for consented human data flattens and Datavena caps out as a niche recruitment channel.
- Closest real companies, as the generator saw them
- Atlas Discovery, Omanta and RonanRx Inc. all consume human biological data to build models or products; Harbor runs trial operations. Datavena sits underneath all of them as the metered, consented data supply they currently assemble ad hoc.
- Main risk
- Pharma buyers refuse to pay marketplace rates while hospital record brokers and trial CROs sell adjacent data cheaply through existing contracts.
Five judges
Each judge scores every idea in the catalog with a named rubric; the venture judge decides whether a card is shown at all (4-5 is venture-grade).
Venture investor
3/5
$250B drug R&D flow is the right size, but consumer data-royalty supply aggregation needs three years of R&D before any buyer pays marketplace rates.
Bootstrapper
1/5
Three years of federated enclave R&D plus device preinstall deals before a single royalty is billed.
Operator
1/5
Three years of R&D to sell data pharma already sources cheaply through CRO and hospital broker contracts, with consumers as the unpaid supply side.
Technologist
3/5
Federated enclave metering is real three-year engineering, but the winner is decided by consumer installed base and device preinstall deals, not by the compute layer.
Risk
1/5
A royalty marketplace for genomes and health records under GDPR consent rules is the heaviest unlicensed regulatory exposure in this batch.
trends
2/5
Consented health-data marketplaces were pitchable in 2023; the NAMs demand story names no dated 2025-2026 regulation or platform move that opens a window.
Similar startups in the directory
Companies whose pitch matches most of the idea's terms (marketplace, biology, earns, royalties, drug, developers, consumer, connect): 121 all-time, 13 from the last two years. Same matching as Idea Check.
Realizse's mission is to accelerate the world's transition to sustainable products. Realizse is a Web3 platform for the circular economy. Realizse creates verifiable assets with digital twins supporting circularity, sustainability, and traceability for supply chain interoperability.
Genomic medicine for transplanted livers.
Developer of a goods comparison platform designed to find out discount deals and offers on consumer durables. The company's platform offers complete transparency by instantly showing shopping options across all retail marketplaces including new, used, refurbished, rental, unbranded and in-store, enabling consumers to compare prices, shop across marketplaces, and maximize savings by making better buying decisions.
Developer of a microstock marketplace designed to connect digital artists and filmmakers for the promotion of digital media. The company's marketplace offers a web-based platform to purchase worldwide stock animation, video footage, after effects templates, apple motion templates, and online music tracks, enabling users to view various forms of digital media and purchase according to their requirements.
Marketplace to get stuff from overseas
Leverages technology to revolutionize payments in emerging markets by making them safer, more convenient, and beneficial for consumers, merchants, and cities
Digital Grid is a retail supply contract or a power supply contract with a service provider using the digital grid platform.
Reprogramming immunomodulation using AI to cure cancer
AI-native CRO for clinical trial operations
AI Infra for real-time vision applications
Building AGI that can innovate.
AI powered reconciliation for high-volume payments companies
The generator's reference companies
Real companies the model named as closest when it wrote the card, with their fate. A check mark is a company the radar could verify in its directory.
Public money in this direction
US federal grants, SBIR/STTR awards and open opportunities from the radar's public-money feed, matched to the idea's terms; the sector totals give the context.
8
grants and programs matching the idea
1127
startup-relevant grants in Healthcare and bio
$590M
awarded in the sector, tracked
130
opportunities open now in the sector
- Economical, easy-to-use and highly sensitive illicit drugs detection in bodily fluids using surface-enhanced Raman scattering (SERS).awardhigh relevance
NIH / NIDA · SBIR phase I · $311K · posted 2026-07-01
- Modeling Receptor-ligand interactions for Drug Discoveryfrom Cryo-EM data using AIawardhigh relevance
NIH / NIGMS · SBIR phase I · $218K · posted 2025-09-01
- A Real-Time Mass Spectrometry Platform for In-Process Monitoring and Cell State Analysisawardhigh relevance
NIH / NIGMS · SBIR phase I · $303K · posted 2025-08-02
- Investigating Ultra-High-Quality Graphene-Based Cryo-EM Device Architecture for Higher Reproducibility, Speed, and Resolutionawardhigh relevance
NIH / NIGMS · SBIR phase I · $307K · posted 2025-08-01
NIH / NIAMS · SBIR phase I · $313K · posted 2025-08-01
- Implantable Intelligent Engineered System to Enable Virtual Bidirectional Muscle-Prosthesis Mechanical Interaction for Amputeesawardhigh relevance
National Science Foundation · M3X - Mind, Machine, and Motor, Special Initiatives, Dynamics, Control and System D · $809K · posted 2026-08-21
- I-Corps: Translation Potential of an Artificial Intelligence (AI) Co-Scientist Platform for messenger Ribonucleic Acid (mRNA) Therapeutics Designawardhigh relevance
National Science Foundation · I-Corps · $50K · posted 2026-08-19
NIH / NCATS · STTR phase I · $350K · posted 2026-08-17
Market signal
What the radar sees in Healthcare and bio: new companies by cohort year, the forming YC batch, and outcomes since the February snapshot.
Healthcare and bio · 130 → 118 → 216 → 173 → 71 new companies 2022 → 2026 · 92% aliveYC S26: 14 in this cluster, 6% of the batch (was 4% in X26) (F26 is still forming: 21 listed)Since February, of 444 YC companies here: 4 acquired, 5 shut down, 37 rewrote their pitch
Design attributes
The card is one cell of a designed set: every axis below was chosen before the text was written, and the text had to realize it.
- Buyer
- Consumer
- Business model
- Marketplace
- Path to 100x
- Creates a new category
- Market size
- $100B+ market
- Capital intensity
- Capital-medium (ops, field teams)
- Speed to revenue
- R&D first, revenue after 3 years
- Technical depth
- Deep tech: ML, hardware, bio
- Go-to-market
- Self-serve
- Moat
- Distribution moat
- Geography
- Global from day one
- Regulation
- Some regulation
- Vibe
- Hot space
Listed under
An idea sits in its own sector and in any sector its text clearly touches.
More ideas like this
Health and bio · Healthcare and bio
Bylaw Health
The licensed medical group behind your API call, in fifty states.
Bylaw Health holds the professional corporations, state clinician licenses, supervision agreements and payer enrollments in every US state, and exposes them as endpoints: create a clinician, attach a supervising physician, enroll a location with a payer, submit an encounter under a compliant entity.
Health and bio · Healthcare and bio
Bayworks
Licensed GMP manufacturing bays for personalized therapies, sold as bookable capacity.
Bayworks builds standardized, FDA-registered cleanroom modules inside hospital systems and partner CDMO sites, then runs a marketplace where drug sponsors book manufacturing slots by the batch instead of signing multi-year suite reservations.
Health and bio · Healthcare and bio
Assaygrid
Predicts which lab runs will fail before reagents are consumed, across every instrument vendor.
Assaygrid connects to the instrument fleet of pharma, biotech and industrial R&D organizations, learns from run telemetry, reagent lots, operator steps and outcomes, and flags runs likely to fail plus the parameter change that fixes them.
Health and bio · Healthcare and bio
Overturn
Agents that fight payer denials for health systems, then sell what wins.
Overturn deploys an agent workforce inside a health system's revenue cycle that reads each denial, pulls the governing payer medical policy, assembles the clinical record and files the appeal, working through existing EHR and clearinghouse integrations rather than new infrastructure.
Health and bio · Healthcare and bio
Labmesh
Agents that design, order and run preclinical experiments across a global lab network.
Labmesh gives a biotech or pharma scientist an agent that takes a hypothesis, decomposes it into assays, prices and routes each assay to a contract lab on its network, tracks samples, and returns structured results with the raw instrument files.
Health and bio · Healthcare and bio
ChartRail
The consented medical-records rail every AI clinic runs on.
An API that lets AI-native care companies pull a patient's complete medical record with verifiable consent, by operating as a qualified participant in the national health information exchange framework and as a registered clearinghouse.
Fictional company written 2026-08-26 from MarkosWeb data; the companies, grants and numbers around it are real and tracked. Treat the idea as a research prompt, not a plan.